$ klow --query dose-context --warn PK-mismatch
KLOW peptide dose context: component-level research figures and the pharmacokinetic mismatch.
No human dose guidance exists for the blend. What follows is what the component studies measured, and the structural reason a single vial cannot hold all four at matched exposures.
TL;DR — dose context
KLOW peptide is a four-part research blend. There is no validated human dose for the combination — no clinical trial has tested it. What exists is the canonical research-vial composition (80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg) and the separate dose figures from the individual component literatures, which are mostly rodent studies and not directly translatable to humans. This page documents that research-dose context. It does not recommend any dose, frequency, or route for human use.
KLOW peptide dosage
The most widely cited KLOW research-vial composition across independent compounders is 80 mg total: GHK-Cu 50 mg (about 62.5% by mass), BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. This split is the research convention, not an approved pharmacopeial specification. No clinical trial has validated this ratio or any other ratio for the blend.
No validated human dosing exists for KLOW. Component research doses differ widely by species and route and are not additive into a single 'KLOW dose.' The rodent doses used in individual studies — 10 μg/kg for BPC-157 Achilles tendon work [9], 10 pg to 10 μg for thymosin beta-4 wound models [3], nanomolar concentrations for KPV cell studies [6] — represent different experimental contexts, different routes, and different target tissues.
KLOW peptide dosage and frequency
No dosing frequency has been established for KLOW or for any of its four components in human research. The published component literature measured single-administration or short-course treatment in rodents or in cell culture, not human dosing schedules.
The pharmacokinetic mismatch complicates any co-administration rationale: BPC-157 has a very short elimination half-life (under approximately 30 minutes based on informal pharmacokinetic observations in rodent models). The tripeptides KPV and GHK-Cu are smaller molecules and clear even faster in biological systems. The TB-500 heptapeptide fragment is likely distinct from the half-life of full-length native thymosin beta-4. A single co-dissolved vial therefore cannot sustain all four components at matched plasma concentrations — the four arms are at different exposure levels from the moment of administration, a structural gap in the combination rationale.
KLOW dosage
The component-level dose figures from published rodent studies (not human dose recommendations):
BPC-157: 10 μg, 10 ng, or 10 pg per rat via intraperitoneal injection or local injection in the Achilles tendon study [9]. The first-in-human IV pilot administered 10 mg on day 1 and 20 mg on day 2 in 250 cc saline as a 1-hour infusion in two adults — a safety observation, not an efficacy dose [17].
TB-500 / thymosin beta-4: topical or intraperitoneal Tβ4 in the full-thickness rat wound model; the keratinocyte migration assay was active at as little as 10 pg [3].
KPV: 10 nM in intestinal epithelial cell culture; 100 μM in drinking water in mouse colitis models [6]. KPV's PepT1 Km is approximately 160 μM, the concentration at which the transporter operates at half-maximal velocity.
GHK-Cu: 1-10 nM in the cell-culture validation studies for the gene-expression analysis [7]; topical formulations in the clinical skin studies [5].
These are research dose contexts, not human administration guidelines.
Reconstitution and stability notes
The lyophilized KLOW blend is reconstituted with bacteriostatic water for laboratory handling. Reconstituted solution is typically refrigerated. Copper(II) in GHK-Cu can participate in redox chemistry — a theoretical compatibility consideration when co-dissolved with three other peptides in one vial. This question has not been formally characterized for this mixture; no published study has assessed the stability or interaction chemistry of the four-peptide combination in solution.
Routes studied in the component literature
Subcutaneous injection is the most commonly discussed research-handling route for the blend. The component literature also covers: topical application for GHK-Cu (the primary route in clinical cosmetic/wound data [5]); oral and targeted-delivery for KPV (including the PepT1-mediated gut delivery route [6]) and BPC-157 (BPC-157 has rodent data for oral, intraperitoneal, and intra-articular routes); and intra-articular for BPC-157 in joint models. The TB-500 fragment has been studied subcutaneously in animal models. Route selection in component studies was tissue-specific; no route has been established for the combination.